Skip to content

post

THANKS GOOGLE TRANSLATORS…….

    Thanks, Google translator Gracias traductor de google Merci, traducteur Google 谢谢,谷歌翻译 マイレビュー спасибо, гугл-переводчик 감사,구글 번역기 cảm ơn, google translator danke, google übersetzer GDMeds leading online pharmaceutical company has a support hand ofGoogle translators for their well growth in their business. Google translators are a free multilingual machine translation service developed byGoogle, to translate text.… Read More »THANKS GOOGLE TRANSLATORS…….

    GDMEDS OPENING SHORTLY CUSTOMER SERVICE CENTRE IN GODS OWN COUNTRY- KERALA.

      GDMeds one of the leading online pharmacy has released fantastic news as they are going to build up their strength in Kerala. GDMeds was started by the intention of Dr.Liya and Vincent Cooper to help patients purchase reliable and cheap generic anti-cancer medicines since 2014, they started up their business as a ground level business… Read More »GDMEDS OPENING SHORTLY CUSTOMER SERVICE CENTRE IN GODS OWN COUNTRY- KERALA.

      FDA Approves Two-Drug Combo Mavyret for HCV in Adolescents.

        The US Food and Drug Administration (FDA) approved glecaprevir and pibrentasvir (Mavyret, AbbVie) tablets for the treatment of all six hepatitis C virus (HCV) genotypes in children ages 12 to 17 years. The FDA approved the drug combination for adults with all six genotypes of hepatitis C on Aug. 3, 2017. “Direct-acting antiviral drugs reduce the amount of HCV in the… Read More »FDA Approves Two-Drug Combo Mavyret for HCV in Adolescents.

        Finding the ‘Sweet Spot’ With Corticosteroids in Cancer Care.

          Mark Kris from Memorial Sloan Kettering, speaking again about the use of corticosteroids in oncology. Clearly, they’re one of our go-to agents, part of our standard antiemetic regimens, a cornerstone of the management of neurologic complications, and part of the management of many side effects, including dyspnea and anorexia. It’s very important to use corticosteroids… Read More »Finding the ‘Sweet Spot’ With Corticosteroids in Cancer Care.

          Newly Approved Osteoporosis Drug Is ‘Promising’ and ‘Welcome’

              In medicine, lessons from rare genetic disorders can sometimes be turned into treatment for a common disease. Since the discovery that patients with sclerostin deficiency have surprisingly high bone mass,[1,2,3] inhibiting sclerostin has been an appealing strategy to treat osteoporosis. Romosozumab is a humanized monoclonal antibody against sclerostin, and its approval by the US Food and Drug Administration… Read More »Newly Approved Osteoporosis Drug Is ‘Promising’ and ‘Welcome’

            FDA Approves Letairis (Ambrisentan) Generics for PAH.

              The US Food and Drug Administration (FDA) has approved four generic versions of Gilead Sciences’ Letairis (ambrisentan), an endothelin receptor antagonist indicated for treatment for pulmonary arterial hypertension (PAH). The FDA first approved Letairis for PAH in 2007. Three generics are from Mylan Pharmaceuticals, Watson Laboratories, and Sun Pharma Global. The fourth generic is from Zydus Pharmaceuticals. In order to accommodate all four… Read More »FDA Approves Letairis (Ambrisentan) Generics for PAH.

              Long-Term Androgen Deprivation Underused for Prostate Cancer.

                  Long-duration androgen deprivation therapy (ADT) is widely underused in men, especially African Americans, who are undergoing definitive external beam radiotherapy (EBRT) for high-grade prostate cancer, a new U.S. study has found. Nearly a quarter of patients in the population-based retrospective trial received no long-term ADT, and fewer than one in seven received the recommended… Read More »Long-Term Androgen Deprivation Underused for Prostate Cancer.